<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582033</url>
  </required_header>
  <id_info>
    <org_study_id>SGNBCMA-001</org_study_id>
    <nct_id>NCT03582033</nct_id>
  </id_info>
  <brief_title>A Safety Study of SEA-BCMA in Patients With Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple&#xD;
      myeloma (MM) and what side effects (unwanted effects) may occur.&#xD;
&#xD;
      The study will have several parts. In Parts A and B, participants get SEA-BCMA by itself.&#xD;
      This part of the study will find out how much SEA-BCMA should be given for treatment and how&#xD;
      often. It will also find out how safe the treatment is and how well it works.&#xD;
&#xD;
      In Part C of the study, participants will get SEA-BCMA and dexamethasone. In Parts D and E,&#xD;
      participants will get SEA-BCMA, dexamethasone, and either pomalidomide or nirogacestat.&#xD;
      Dexamethasone and pomalidomide are both drugs that can be used to treat multiple myeloma.&#xD;
      Nirogacestat is an experimental drug that can be used with SEA-BCMA to treat multiple&#xD;
      myeloma. These parts of the study will find out whether these drugs are safe when used&#xD;
      together.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Through 30-37 days following last dose, up to approximately 3 years</time_frame>
    <description>Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with laboratory abnormalities by grade</measure>
    <time_frame>Through 30-37 days following last dose, up to approximately 3 years</time_frame>
    <description>Grades for laboratory abnormalities will be evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Through up to 28 days following first dose</time_frame>
    <description>To be summarized using descriptive statistics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) outcome: Cmax (maximum serum concentration)</measure>
    <time_frame>Through 30-37 days following last dose, up to approximately 3 years</time_frame>
    <description>To be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK outcome: AUC (area under the serum concentration-time curve)</measure>
    <time_frame>Through 84 days following first dose</time_frame>
    <description>To be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SEA-BCMA antitherapeutic antibodies (ATA)</measure>
    <time_frame>Through 30-37 days following last dose, up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response per the IMWG uniform response criteria</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>International Myeloma Working Group (IMWG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>The proportion of patients with stringent complete response, complete response, very good partial response, or partial response per investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response (OR)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>The time from first documentation of OR to the first documentation of disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response (CR)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>The time from first documentation of CR to the first documentation of disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>The time from the start of study treatment to the first documentation of disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>The time from the start of study treatment to the date of death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">305</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Parts A and B: SEA-BCMA Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-BCMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: SEA-BCMA + Dexamethasone Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-BCMA + dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: SEA-BCMA + Pomalidomide + Dexamethasone Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-BCMA + dexamethasone + pomalidomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E: SEA-BCMA + Nirogacestat + Dexamethasone Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-BCMA + dexamethasone + nirogacestat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEA-BCMA</intervention_name>
    <description>Given into the vein (IV; intravenously)</description>
    <arm_group_label>Part C: SEA-BCMA + Dexamethasone Combination Therapy</arm_group_label>
    <arm_group_label>Part D: SEA-BCMA + Pomalidomide + Dexamethasone Combination Therapy</arm_group_label>
    <arm_group_label>Part E: SEA-BCMA + Nirogacestat + Dexamethasone Combination Therapy</arm_group_label>
    <arm_group_label>Parts A and B: SEA-BCMA Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given by mouth (orally) or by IV</description>
    <arm_group_label>Part C: SEA-BCMA + Dexamethasone Combination Therapy</arm_group_label>
    <arm_group_label>Part D: SEA-BCMA + Pomalidomide + Dexamethasone Combination Therapy</arm_group_label>
    <arm_group_label>Part E: SEA-BCMA + Nirogacestat + Dexamethasone Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pomalidomide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Part D: SEA-BCMA + Pomalidomide + Dexamethasone Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nirogacestat</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Part E: SEA-BCMA + Nirogacestat + Dexamethasone Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of MM&#xD;
&#xD;
          -  Must have MM that is relapsed or refractory&#xD;
&#xD;
          -  Parts A, B, C, and E: Has received a proteasome inhibitor, an immunomodulatory drug,&#xD;
             and an anti-CD38 antibody&#xD;
&#xD;
          -  Part D only: Has received 2 prior lines of therapy and has not previously received&#xD;
             pomalidomide&#xD;
&#xD;
          -  Measurable disease, as defined by at least one of the following: (1) serum M protein&#xD;
             0.5 g/dL or higher, (2) urine M protein 200 mg/24 hour or higher, and (3) serum&#xD;
             immunoglobulin free light chain (FLC) 10 mg/dL or higher and abnormal serum&#xD;
             immunoglobulin kappa lambda FLC ratio.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) status score of 0 or 1&#xD;
&#xD;
          -  Life expectancy of greater than 3 months in the opinion of the investigator&#xD;
&#xD;
          -  Adequate hematologic, renal, and hepatic function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with a BCMA-directed therapy&#xD;
&#xD;
          -  History of another malignancy within 3 years&#xD;
&#xD;
          -  Active cerebral or meningeal disease related to the underlying malignancy&#xD;
&#xD;
          -  Uncontrolled Grade 3 or higher infection&#xD;
&#xD;
          -  Prior antitumor therapy that is not completed at least 4 weeks prior to first dose of&#xD;
             study drug, or at least 2 weeks if progressing. Prior CAR-T-cell therapy must be&#xD;
             completed 8 weeks before first dose of study drug.&#xD;
&#xD;
          -  Combination therapy only:&#xD;
&#xD;
               1. Known intolerance to corticosteroids&#xD;
&#xD;
               2. Uncontrolled psychoses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phoenix Ho, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Michaela Liedtke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Robert Rifkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>James Hoffman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center / University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Michael Tomasson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Al-Ola Abdallah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Mark Schroeder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Ruben Niesvizky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center / University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Brea Lipe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute/Oncology Assc of Oregon</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Yasenchak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Jason Melear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Damian Green, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RRMM</keyword>
  <keyword>Antibodies, monoclonal</keyword>
  <keyword>Antigens, BCMA</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Hematologic diseases</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

